Evaluation status available after sign-in
About the journal
Lung Cancer: Targets and Therapy is an open-access journal published by Dove Medical Press in United Kingdom, publishing in english. It is listed in DOAJ according to the sources read. Declared publication charge: 3,940 USD. Declared review time at DOAJ: 16 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Dove Medical Press
- ISSN
- 1179-2728
- Country
- United Kingdom
- Languages
- english
- Access
- Open access
- Declared publication charge
- 3,940 USD
- Articles in DOAJ
- 197
- Declared review time
- 16 weeks
- Declared peer-review model
- other
- Official website
- https://www.dovepress.com/lung-cancer-targets--therapy-journal
Index listings
- DOAJ · 2010-12-21
- Indexing
- DOAJ
- APC
- 3,940 USD
- Declared review time (DOAJ)
- 16 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
197
Most recent article
2 months ago
Average review time (journal-declared via DOAJ)
16weeks
Works in OpenAlex
216
Last recorded publication year
2026
Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
35
i10-index
103
From OpenAlex open data (CC0).
Editorial & policy13
- Last DOAJ review date
- 2026-04-27
- Added to DOAJ
- 2010-12-21
- Declared plagiarism screening
- Declared
- Other fees beyond APC
- No
- Declared digital preservation
- CLOCKSSPMC
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSS
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 85%
- ORCID iDs in current deposits
- 91%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
- APC waiver policy
- View policy
- Peer-review policy
- View policy
Identity & continuity3
- Alternate titles
- Journal of lung cancer : targets and therapyLung cancer, targets and therapy
- Source type
- journal
- NLM unique ID (PubMed)
- 101632521
Classification2
Subjects (DOAJ)
Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
LCC codes
RC254-282
Subject areas
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
Show all subjects (75)
- Lung Cancer Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Cancer-related Molecular Pathways
- Cancer Mechanisms and Therapy
- Cancer-related Molecular Pathways
- Occupational and environmental lung diseases
- Neuroendocrine Tumor Research Advances
- Neuroendocrine Tumor Research Advances
- Advanced Radiotherapy Techniques
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Cancer Mechanisms and Therapy
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Cancer survivorship and care
- Occupational and environmental lung diseases
- Hepatocellular Carcinoma Treatment and Prognosis
- Pleural and Pulmonary Diseases
- Radiomics and Machine Learning in Medical Imaging
- Protein Kinase Regulation and GTPase Signaling
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Metastasis and carcinoma case studies
- Advanced Radiotherapy Techniques
- Gastric Cancer Management and Outcomes
- Inflammatory Biomarkers in Disease Prognosis
- Genetic factors in colorectal cancer
- Peptidase Inhibition and Analysis
- Advanced Radiotherapy Techniques
- Peptidase Inhibition and Analysis
- Genetic factors in colorectal cancer
- Inflammatory Biomarkers in Disease Prognosis
- Gastric Cancer Management and Outcomes
- Cancer, Hypoxia, and Metabolism
- Inflammatory Biomarkers in Disease Prognosis
- Lymphoma Diagnosis and Treatment
- Cancer, Hypoxia, and Metabolism
- Epigenetics and DNA Methylation
- Angiogenesis and VEGF in Cancer
- Lymphoma Diagnosis and Treatment
- Cancer survivorship and care
- Epigenetics and DNA Methylation
- Cancer survivorship and care
- Medical Imaging and Pathology Studies
- Intraperitoneal and Appendiceal Malignancies
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Drug Transport and Resistance Mechanisms
- Cancer Cells and Metastasis
- Smoking Behavior and Cessation
- Brain Metastases and Treatment
- Pharmacogenetics and Drug Metabolism
- Breast Cancer Treatment Studies
Keywords (DOAJ)
- lung cancer
- palliative care
- cancer screening
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ